Microsoft is applying its Project Hanover AI to Jackson Laboratory's Clinical Knowledgebase to help tumor boards find appropriate therapies based on tumor mutations.
WUSTL spinout PercayAI will provide augmented intelligence technology to Canopy Biosciences' RNA-seq and NanoString tests to inform drug discovery.
By participating in the project, the company, located in Tokyo, hopes to improve its cloud-based data management services while winning over new customers.
The software, presented at the ISMB/ECCB conference, helps researchers fill in gaps in the human epigenome thanks to 3D deep-learning techniques.
The longtime quest of one Microsoft data scientist to stop infant crib deaths has grown into a genomics and AI research program with lofty goals.
University of Crete spinout Gnosis Data Analysis is adding AI capabilities to Indivumed's IndivuType multi-omics cancer research platform.
With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
Japanese software giant NEC invests in AI-centric software company BostonGene to advance immuno-oncology and other targeted cancer treatments.
French startup OmicX has built an AI-based search engine for omics-related knowledge to help biomedical researchers find protocols in published literature.
Circuit Clinical will collect, store, and process blood, tissue, and bodily fluids through the UB biorepository for genomic sequencing and microbiome studies.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.